gens to T cells. 3 Mature DCs have several morphological and phenotypical properties which make them potent APCs. Dendritic cells express high levels of HLA class I and II (especially DR), and co-stimulatory molecules such as CD40, CD80 and CD86 which bind to their T cell counterparts, CD40L, CD28 and CTLA-4 respectively. 4 Myeloid DCs activated by different stimuli such as CD40L, produce and secrete IL-12, a potent T cell stimulatory cytokine which induces the production of IFN␥ by T cells and NK cells. 5, 6 The unique ability of DCs to prime naive T cells and to present antigens effectively has led to their use as 'natural adjuvants' in experimental tumour immunotherapy. 7 At present, efforts are being made to generate DCs ex vivo from different sources. Dendritic cells can be obtained from peripheral blood monocytes primed by GM-CSF and IL-4 to differentiate into DCs [8] [9] [10] and from CD34 ϩ progenitor cells from either bone marrow or cord blood, requiring GM-CSF and TNF␣ for their differentiation. 11, 12 Other cytokines including SCF, Flt3-L and TGF␤1 have also been extensively used. Stem cell factor increases the number of initial pluripotent stem cells in CD34
ϩ -derived DC cultures, 13 whereas Flt3-L increases the number of DCs in lymphoid and non-lymphoid tissues in mice 14 and promotes an extensive amplification of human CD34 ϩ progenitor cells in culture. 15 TGF␤1, in the presence of GM-CSF and IL-4, induces differentiation of monocytes to Langerhans cells. 16 IL-4 has also been used to inhibit the monocyte differentiation pathway and to favour the DC pathway when CD34 ϩ cells are used. 8, 17 In addition to the cytokines, the source of serum used to obtain differentiated DCs in vitro is also important. Experiments to date have used different sources of serum proteins and factors including human adult blood serum (ABS), human plasma and fetal calf serum (FCS). We have studied and compared the ability of autologous cord blood plasma (ACBP) to promote the differentiation of DCs from cord blood enriched CD34 ϩ cells. Dendritic cells differentiated in ACBP or ABS cultures were tested for the expression of HLA class II (DR and DQ) co-stimulatory molecules (CD40, CD80 and CD86) and the CD83 and CD1a DC markers. The allostimulatory capacity of cord blood CD34 ϩ derived DCs was also assessed using the mixed lymphocyte:dendritic cell reaction (MLDCR).
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Materials and methods
Cell culture
Human CD34
ϩ progenitor cells were enriched from cord blood obtained from normal full-term deliveries collected following Ethics Committee approval and consent from all mothers. Prior to Ficoll separation, plasma was obtained by a brief centrifugation process. All serum or plasma samples were heat inactivated at 56°C for 30 min. The plasmadepleted blood was diluted 1:1 in RPMI and the mononuclear cells separated by a Ficoll-Hypaque density centrifugation (Nycomed, Birmingham, UK). The mononuclear cell fraction was then subjected to a negative selection process. Briefly, the cells were first incubated with a CD3-depleting antibody cocktail, plus a CD34 enrichment cocktail for 15 min at room temperature (RT). This enrichment cocktail contains a mixture of antibodies to deplete cells expressing CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b and glycophorin A (Stemcell Technologies, Vancouver, Canada). This incubation was followed by the addition of a magnetic colloid for a further 15 min. Finally, the cells were separated over a magnetic column (Stemcell Technologies). Using this approach, the yield of CD34 ϩ cells obtained was between 0.1 to 1% of the total mononuclear cells, depending on the sample. The purity of the cell separation used in all the experiments was higher than 75%, and in fact the majority of the samples analysed contained over 90% CD34 ϩ cells (data not shown). The enriched CD34 ϩ cells were washed twice in PBS and approximately 25 to 30 × 10 5 cells/ml were plated in IMDM culture medium (Gibco BRL, Paisley, UK) containing, for comparative purposes, either 5% pooled (n = 3) AB ϩ ABS, or 10% ACBP or 10% HCBP (obtained from a different donor) and different mixtures of cytokines. Fresh cytokines and medium were added to the cell cultures on days 4 and 8 by carefully replacing half of the culture medium. On day 14, unless otherwise indicated, the cells were collected by gentle pipetting and further processed. The quantity of serum proteins at working concentrations was measured by direct reading in a spectrophotometer at 280 nm (GeneQuant II, Pharmacia Biotec, Uppsala, Sweden) and were found to be similar in all cultures (data not shown).
Cytokines
All cytokines used in this study were of human recombinant origin (R&D Systems, Oxford, UK) and used as indicated at the following concentrations: GM-CSF 20 ng/ml, IL-4 20 ng/ml, TNF␣ 20 ng/ml, SCF 100 ng/ml, Flt3 ligand 100 ng/ml. Throughout the text we have used the terms rich and poor mixture of cytokines to define those cultures containing either all the cytokines mentioned above (rich mixture) or GM-CSF and TNF␣ only (poor mixture).
Immunostaining and flow cytometry
Cultured cells were collected and washed twice in PBS Dulbecco's. The following FITC or PE conjugated antibodies to the specific markers and isotype controls were used: CD1a (Ortho Diagnostic Systems, Raritan, NJ, USA), CD40, CD83 (Immunotech, Marseille, France) CD14, CD16, CD19, CD25, CD80, CD86, HLA DR, HLA DQ (Pharmingen, San Diego, CA, USA). After 15 min at RT, the cells were washed and analysed in a FACSCAN flow cytometer using standard CellQuest acquisition software (Becton Dickinson, San Jose, CA, USA). All samples were gated using forward and side scatter to exclude dead cells. Both the percentage of cells expressing CD markers and also the fluorescence intensity defined by the geometric (G) mean of the CD expressed by the cells were taken into account in the analyses performed. Statistical analyses were performed by Student's t test. A value of P Ͻ 0.05 was considered significant.
Mixed lymphocyte:dendritic cell reaction (MLDCR)
In order to assess the allostimulatory capacity of CD34 ϩ -derived DCs, these cells were irradiated (25 Gy) and cultured with purified CD4 ϩ T cells (50 000 cells/well) at different cell ratios. Triplicate wells were set up. CD4
ϩ T cells were obtained by a negative selection process with a T cell enrichment cocktail (Stemcell Technologies) as above. The purity of this population was Ͼ90% in all experiments. After 4 days, 3 H-thymidine (1 Ci/well) was added and the cells were incubated for a further 12 to 18 h. T cell proliferation was measured on a beta-counter (Packard Biosciences, Berks, UK). The results are presented as the mean c.p.m. values of triplicate cultures. All the experiments comparing ACBP and ABS were made in parallel, using the same T cells as responders.
Results
Phenotype of differentiated DCs after 14 days in culture
Cord blood-enriched CD34 ϩ cells were cultured in ACBP or ABS in medium containing GM-CSF, SCF, IL-4, Flt3-ligand and TNF␣ (rich mixture of cytokines). After 7 days in culture some morphological differences were observed. Cells in ABS showed an increased capacity to spread and attach to the culture plate whilst this feature was not observed in ACBP cultures (data not shown). After 14 days, cell recovery was significantly (P Ͻ 0.01) greater in ABS cultures than in ACBP cultures (520 000 Ϯ 190 000 vs 150 000 Ϯ 75 000 total cells, n = 4). On day 14, the phenotypic features of these cells were measured by flow cytometry. The results showed that over 90% of the cell population expressed HLA class II molecules (DR ϩ DQ), and other DC associated markers such as CD40, CD1a, CD80, CD83 and CD86 were expressed by different proportion of cells (Figure 1a ). Cells cultured in either ABS or ACBP were able to differentiate into DCs showing a similar percentage of cells expressing these markers, although cells cultured in ACBP showed a slight but significant increase in the percentage of cells expressing CD83 and CD86 markers. The intensity of expression (mean) was similar in both ACBP and ABS culture derived cells (Figure 1b) . These results suggest that under these conditions both ACBP and ABS could equally support the differentiation of CD34 ϩ cells into DCs. In order to investigate whether this effect could be due to the composition of cytokines used, cord blood-enriched CD34 ϩ cells were cultured in ACBP or ABS in GM-CSF and TNF␣ only (poor mixture of cytokines). In this case IL-4 was not added to the cultures. The cell recovery under these conditions was similar to that obtained above, 665 000 Ϯ 149 000 for ABS vs 191 000 Ϯ 117 000 for ACBP (total cells, n = 3, P Ͻ 0.01). However, in this case, the DC phenotype of the cells was greatly enhanced in the ACBP cultures, as reflected by the higher percentage of cells expressing CD1a, CD83 and CD86 (Figure 2a) . In contrast, CD14 expression was greatly enhanced in ABS cultures, whereas it remained at low levels in ACBP cultures. Furthermore, a great number of the cells obtained in ABS had the same shape, size and appearance as monocytemacrophages showing an ability to attach to the culture wells (data not shown). The effect of ACBP on DC differentiation was also reflected by the mean values of DR, DQ, and CD40 expression which were higher in ACBP cell cultures, while the CD14 mean value was higher in ABS cultures (Figure 2b ). These results suggest that ACBP was by itself able to induce DC differentiation from CD34
ϩ cord blood cells in cultures containing GM-CSF and TNF␣ only. On the other hand, cells obtained in the presence of ABS were a mixture of 'less mature' DCs and monocytemacrophage cells as reflected by the lower expression of CD83 and the high expression of CD14.
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To further confirm the effect of ACBP on DC differentiation, the phenotype of cord blood CD34 ϩ cells differentiated in either a rich or poor mixture of cytokines, but using ACBP as source of serum factors, was compared. The percentage of positive cells and mean values of cells obtained using ACBP in either the rich or poor mixture of cytokines were the same (see white boxes in Figures 1 and  2) , indicating that the use of additional cytokines had no significant effect in the differentiation of cord blood CD34 ϩ cells into DCs.
The ability of HCBP to generate DCs was also tested. The results showed that under the same conditions cells cultured in HCBP had DC characteristics similar to those obtained in ACBP (data not shown). Thus, the ability to generate DCs from enriched CD34
ϩ cord blood cells cultured in the poor mixture of cytokines (GM-CSF and TNF␣ Bone Marrow Transplantation only) can be supported by either homologous or autologous cord blood plasma.
MLDC reactions
The results obtained in the MLDC reactions showed that the DCs generated in ACBP had a higher capacity to induce CD4 ϩ T lymphocyte proliferation compared to those generated in ABS. The capacity of DCs to cause allostimulation was assessed using either cord or adult purified T cells. DCs generated in the presence of ACBP showed a similar profile of allostimulation either they were cultured in the presence of rich or poor mixture of cytokines (Figure 3 , panels a and b). By contrast, DCs generated in ABS only showed allostimulation capacity when cultured in the presence of rich mixture of cytokines, whereas those generated in the presence of the poor mixture of cytokines were unable to induce a strong allostimulatory response ( Figure  3, panel c and d) . Also, the allostimulatory capacity of DCs generated in ACBP was slightly higher than that obtained with the ABS-derived DCs. Cells generated in the presence of homologous plasma showed similar stimulation indices to autologous plasma DCs (data not shown). However, in all cases, higher stimulation capacities were apparent at high T cell:DC ratios.
Discussion
The generation of dendritic cells from different cell sources is considered to be of major importance as possible immunotherapy treatment. The number and maturity of the DCs generated may determine their potential clinical use. In the last few years DCs have been identified as potentially powerful adjuvants for inducing immune responses to tumours 18 as it has been postulated that the defective immune responses to tumours could be due to deficient antigen presentation of the relevant tumour antigens. It is possible that this deficiency may be due to a lack of DC differentiation as a result of the tumour process. MenetrierCaux et al 19 have described the role of IL-6 and M-CSF derived from tumour cells in the inhibition of differentiation of DCs from CD34 ϩ precursors. In addition, IL-10 and vascular endothelial growth factor (VEGF) both secreted by tumour cells have been shown to inhibit the development of monocyte-derived DCs. 20 Other studies have suggested that an acidic environment in the tumour surrounding areas may contribute to the lack of monocytederived DC maturation and function. 21 Therefore, the possibility to promote DC differentiation may be a useful approach to develop competent DCs to induce immune responses to tumours or infections.
One of the main sources of in vitro-derived DCs are monocytes. The main advantage of this model is that monocytes are a large source of easily obtainable cells that can be directed to a DC phenotype. The other major source of DCs are the CD34 ϩ progenitor cells. In this study we describe the generation of mature DCs from CD34
ϩ cord blood cells in the presence of ACBP and using GM-CSF and TNF␣ only as differentiation cytokines.
The majority of the protocols described so far have used either fetal calf serum (FCS) or adult blood serum (ABS) to differentiate DCs. 11, 15, 21, 22 Rosenzwajg et al 22 reported a method to generate DCs in vitro from CD34 ϩ cord blood precursors using FCS. However, the use of FCS in DC cultures may limit their potential use in clinical immunotherapy. 23 Due to the time required to generate DCs in culture, the exposure to serum antigens could induce significant variables. On the other hand, the use of homologous AB serum could have detrimental side-effects in the recipient, e.g. transmission of infections. These limitations could then be overcome by using autologous plasma (AP) as a source of protein and serum factors. AP has the additional advantage that it is of the same origin as the cells, so it is likely to be less hazardous. Nicola et al 24 have shown that by using AP they were able to generate mature DCs from adult CD34 ϩ cells without the addition of IL-4 or IL-13. Nevertheless, they used a rich mixture of cytokines (GM-CSF, TNF␣, SCF and FLt3-L) to generate those DCs. The results presented in this study show that in the presence of ACBP, DCs can be generated from cord blood CD34 ϩ cells using GM-CSF and TNF␣ only. Thus, ACBP could substitute or even improve the effect of IL-4 added to the ABS cultures to block the monocytic differentiation pathway and to promote DC. 8, 17 Although cell yields are higher using ABS, it is still possible to obtain approximately six times the initial number of cultured cells using ACBP. The higher cell yields obtained with ABS were due, at least in part, to the higher amount of apoptosis detected in ACBP cultures (data not shown).
One of the cytokines involved in promoting the monocytic differentiation pathway is M-CSF. 25 M-CSF is secreted by uterine glandular epithelial cells 26 as well as other cell types, supports the growth of placental trophoblasts 27 and is increased in serum during pregnancy. 26 In fact, M-CSF is also present in cord blood plasma at high concentrations (unpublished observations). However, at this point it is not yet clear whether the effect of ACBP in the differentiation of DCs has any relationship to the presence of M-CSF in cord blood plasma. On the other hand, previous data indicates that tumour-derived M-CSF in combination with interleukin 6 (IL-6) blocks the DC differentiation pathway. 19 Further investigations on the role of cord blood plasma M-CSF on DC differentiation and on the cytokine content of cord blood plasma and adult serum are underway to clarify these observations. With regard to the allostimulatory capacity, the ACBP generated DCs were more effective than the DCs generated in ABS. Moreover, DCs generated in the presence of ACBP either in a rich or poor mixture of cytokines were similarly effective. Interestingly, DCs generated in the presence of ABS and poor mixture of cytokines, were unable to induce a strong alloresponse. One of the features of this population is the expression of CD14 and lower expression of CD83, suggesting a monocyte-macrophage phenotype. These observations support the view that ACBP could substitute or even improve the effect of IL-4 added to the ABS cultures to block the monocytic differentiation pathway and to promote DC differentiation. 8, 17 The use of autologous plasma to generate DCs from adult monocytes and adult CD34 ϩ cells have been previously reported. 21, 28 Ratta et al 28 have found that expansion of CD34 ϩ cell-derived DCs was further enhanced when autologous serum rather than FCS or serum-free medium was used in the cultures. In addition, Eljaafari et al 21 have demonstrated that autologous plasma is more efficient than homologous serum in DC differentiation from adult monocytes. This study has showed that ACBP is able to support the differentiation of DCs from cord blood CD34 ϩ progeniBone Marrow Transplantation tors using a poor mixture of cytokines (GM-CSF and TNF␣ only). Further experiments are now underway to determine the antigen processing and presentation capacities of these cells. Their potential clinical application for immunotherapy protocols requires further investigation.
